Uroplasty (NASDAQ:UPI) will report earnings after markets close on Thursday, May 30th. Uroplasty, Inc. designs, develops, manufactures, and markets medical products primarily for the treatment of urinary incontinence and vesicoureteral reflux. The Company’s principal product is Macroplastique, an injectable, soft tissue bulking agent used to treat certain types of stress urinary incontinence. Uroplasty’s product has been approved for sale throughout the European Union.
Here is your Cheat Sheet to Uroplasty Earnings:
Earnings Expectations: Analysts expect earnings of $-0.04 per share on revenues of $5.59 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.03 to a loss $0.04. For the current year, the average estimate is a loss of $0.16, which is the same as the estimate ninety days ago.
Here’s how Uroplasty has been performing on an annual basis:
|Revenue ($) in millions||15||12||14||21|
|Diluted EPS ($)||-0.24||-0.21||-0.25||-0.21|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||5.60||5.58||5.71||5.59|
|Diluted EPS ($)||-0.03||-0.05||-0.03||-0.03|
Uroplasty has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)